Response to pazopanib-based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma

被引：3

作者：

Limaye, Sewanti ^{[1
]}

Patil, Darshana ^{[2
]}

Akolkar, Dadasaheb ^{[2
]}

Srivastava, Navin ^{[2
]}

Patil, Revati ^{[2
]}

Apurwa, Sachin ^{[2
]}

Patil, Sanket ^{[2
]}

John, Jinumary ^{[2
]}

Gosavi, Rahul ^{[2
]}

Nesargikar, Prabhu ^{[3
]}

Kumar, Prashant ^{[4
,5
,6
]}

Datta, Vineet ^{[2
]}

Bose, Chirantan ^{[2
]}

Raazi, Zarrine ^{[2
]}

Srinivasan, Ajay ^{[2
]}

Datar, Rajan ^{[2
]}

机构：

[1] Kokilaben Dhirubhai Ambani Hosp & Med Res Inst, Mumbai, Maharashtra, India

[2] Datar Canc Genet, Nasik 422010, Maharashtra, India

[3] HCG Canc Ctr, Bengaluru, Karnataka, India

[4] Inst Bioinformat, Bengaluru, Karnataka, India

[5] Manipal Acad Higher Educ, Manipal, Karnataka, India

[6] Somaiya Vidyavihar Univ, Somaiya Inst Res & Consultancy, Mumbai, Maharashtra, India

来源：

CLINICAL CASE REPORTS | 2021年 / 9卷 / 11期

关键词：

combination regimen; encyclopedic tumor analysis; gastric adenocarcinoma; pazopanib; personalized cancer treatment; precision oncology; stomach cancer; PLUS CAPEOX CAPECITABINE; GEMCITABINE COMBINATION; KINASE INHIBITOR; PHASE-II; CANCER; LAROTRECTINIB; CARCINOMA; PATIENT; GROWTH; FUSION;

D O I：

10.1002/ccr3.4986

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti-cancer agents for treatment of Gastric cancers.

引用

页数：5

共 2 条

[1] A refractory case ofCDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report
Lin, Jietao
Yu, Ling
Fu, Yuanfeng
Chen, Hanrui
Zheng, Xinting
Wang, Shutang
Gao, Chan
Cao, Yang
Lin, Lizhu
BMC CANCER, 2020, 20 (01)
[2] Durable Response After Combination Of Concurrent Chemoradiotherapy And Anti-PD-I Therapy In HER2-Negative Advanced Gastric Adenocarcinoma: A Case Report
Yu, Shanshan
Cai, Luya
Lin, Fan
Wu, Xueyuan
Zhang, Cheng
Liu, Xuan
Li, Wenfeng
ONCOTARGETS AND THERAPY, 2019, 12 : 7691 - 7698

← 1 →